{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:09:50Z","timestamp":1789135790327,"version":"build-2803163510"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have transformed the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). However, the inevitable emergence of acquired resistance significantly limits their long-term efficacy. While conventional accounts of resistance have primarily focused on tumor-intrinsic genetic alterations, accumulating evidence highlights the pivotal role of the tumor microenvironment (TME) in mediating therapeutic failure. The TME contributes to EGFR-TKI resistance through multiple interconnected mechanisms, including immunosuppression, extracellular matrix-mediated physical barriers, metabolic reprogramming, and compensatory signaling activation. These complex interactions create a protective niche that enables tumor cells to persist despite EGFR inhibition. Traditional Chinese medicine (TCM), characterized by its multi-component and multi-target properties, offers a potential systems-level approach to modulating the TME. Preclinical studies suggest that TCM-derived interventions may influence immune-cell polarization, stromal and vascular features, and tumor metabolism, thereby affecting EGFR-TKI sensitivity. This review focuses on TME-mediated EGFR-TKI resistance in NSCLC and appraises TCM interventions according to evidence type and directness. We evaluate current preclinical and clinical evidence, identify major limitations, and propose priorities for translational research. The review provides a conceptual framework for evaluating TCM-based combination strategies intended to attenuate EGFR-TKI resistance.<\/jats:p>","DOI":"10.3389\/fphar.2026.1901815","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:34:01Z","timestamp":1789133641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Traditional Chinese medicine reprograms the tumor microenvironment to overcome EGFR-TKI resistance: mechanisms and therapeutic perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuan","family":"Yao","sequence":"first","affiliation":[{"name":"Pharmacy Center, Hefei Cancer Hospital, Chinese Academy of Sciences","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Basic Medical College, Anhui Medical University","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Pharmacy Center, Hefei Cancer Hospital, Chinese Academy of Sciences","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.3390\/nu11102264","article-title":"Astragalus polysaccharides (PG2) enhances the M1 polarization of macrophages, functional maturation of dendritic cells, and T cell-mediated anticancer immune responses in patients with lung cancer","volume":"11","author":"Bamodu","year":"2019","journal-title":"Nutrients"},{"key":"B2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41577-020-0406-2","article-title":"Lactate modulation of immune responses in inflammatory versus tumour microenvironments","volume":"21","author":"Certo","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e21428","DOI":"10.1371\/journal.pone.0021428","article-title":"Elevated BCRP\/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells","volume":"6","author":"Chen","year":"2011","journal-title":"PLOS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13046-019-1234-8","article-title":"Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death","volume":"38","author":"Chen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes"},{"key":"B10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family Reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol. Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3892\/etm.2018.7001","article-title":"Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines","volume":"17","author":"Dai","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci. Adv."},{"key":"B13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cpt.2024.07.001","article-title":"Epithelial\u2013mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)","volume":"3","author":"Dela Cruz","year":"2025","journal-title":"Cancer Pathog. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T-Regulatory cells: key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","article-title":"Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance","volume":"527","author":"Fischer","year":"2015","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.7150\/ijbs.89942","article-title":"The PI3K\/Akt pathway and glucose metabolism: a dangerous liaison in cancer","volume":"20","author":"Fontana","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"B20","doi-asserted-by":"publisher","first-page":"14742","DOI":"10.3390\/ijms241914742","article-title":"Loss of key EMT-regulating miRNAs highlight the role of ZEB1 in EGFR tyrosine kinase inhibitor-resistant NSCLC","volume":"24","author":"Gohlke","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP\u2013dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","article-title":"Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms","volume":"39","author":"Hu","year":"2021","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-16-2300","article-title":"SFK\/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer","volume":"77","author":"Ichihara","year":"2017","journal-title":"Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation\u2013positive non\u2013small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41401-020-0457-8","article-title":"TGF\u03b22-mediated epithelial\u2013mesenchymal transition and NF-\u03baB pathway activation contribute to osimertinib resistance","volume":"42","author":"Jiang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"B30","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/mto.2016.18","article-title":"Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K\/Akt\/mTOR signaling pathways in lung cancer","volume":"3","author":"Jiao","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41598-020-79801-1","article-title":"High expression of hypoxia inducible factor 1\u03b1 related with acquired resistant to EGFR tyrosine kinase inhibitors in NSCLC","volume":"11","author":"Jin","year":"2021","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1573039","DOI":"10.3389\/fimmu.2025.1573039","article-title":"Lactate-mediated metabolic reprogramming of tumor-associated macrophages: implications for tumor progression and therapeutic potential","volume":"16","author":"Jin","year":"2025","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes Osimertinib-Resistant EGFR-Del19\/T790M\/C797S mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-22-1031","article-title":"Cancer-associated fibroblasts in inflammation and antitumor immunity","volume":"29","author":"Kennel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"739843","DOI":"10.3389\/fphar.2021.739843","article-title":"Kanglaite combined with epidermal growth factor receptor-tyrosine kinase inhibitor therapy for stage III\/IV non-small cell lung cancer: a PRISMA-compliant meta-analysis","volume":"12","author":"Kong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1875-5364(25)60802-8","article-title":"General expert consensus on the application of network pharmacology in the research and development of new traditional Chinese medicine drugs","volume":"23","author":"Li","year":"2025","journal-title":"Chin. J. Nat. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"70535","DOI":"10.18632\/oncotarget.12059","article-title":"Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.7150\/thno.62378","article-title":"Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41392-024-01981-3","article-title":"Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.taap.2010.11.014","article-title":"Andrographolide down-regulates hypoxia-inducible factor-1\u03b1 in human non-small cell lung cancer A549 cells","volume":"250","author":"Lin","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1142\/S0192415X24500253","article-title":"Traditional Chinese medicine for cancer treatment","volume":"52","author":"Liu","year":"2024","journal-title":"Am. J. Chin. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1572909","DOI":"10.3389\/fcell.2025.1572909","article-title":"Hypoxia-driven angiogenesis and metabolic reprogramming in vascular tumors","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1158\/0008-5472.CAN-20-1192","article-title":"Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway","volume":"80","author":"Lu","year":"2020","journal-title":"Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3892\/mmr.2020.11686","article-title":"Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer","volume":"23","author":"Lu","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1007\/s00210-024-03729-w","article-title":"Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25\/NUF2 pathway","volume":"398","author":"Lv","year":"2025","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/ph18071077","article-title":"Ginsenoside Rg3 adjunctively increases the efficacy of gefitinib against NSCLC by regulating EGFR copy number","volume":"18","author":"Lv","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.celrep.2019.12.075","article-title":"Periostin promotes colorectal tumorigenesis through Integrin-FAK-Src pathway-mediated YAP\/TAZ activation","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41388-022-02200-5","article-title":"Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, bax activation, or both","volume":"41","author":"Ma","year":"2022","journal-title":"Oncogene"},{"key":"B49","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"B50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2018.04.024","article-title":"Functional cooperation between HIF-1\u03b1 and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR","volume":"121","author":"Meng","year":"2018","journal-title":"Lung Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"8367","DOI":"10.3390\/molecules27238367","article-title":"Natural products as anticancer agents: current status and future perspectives","volume":"27","author":"Naeem","year":"2022","journal-title":"Molecules"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2017.07.002","article-title":"Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib","volume":"111","author":"Oztan","year":"2017","journal-title":"Lung Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"107788","DOI":"10.1016\/j.phrs.2025.107788","article-title":"Targeting tumor-associated macrophage polarization with traditional Chinese medicine active ingredients: dual reversal of chemoresistance and immunosuppression in tumor microenvironment","volume":"216","author":"Qi","year":"2025","journal-title":"Pharmacol. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.lungcan.2023.02.018","article-title":"MET alterations in advanced non-small cell lung cancer","volume":"178","author":"Sakamoto","year":"2023","journal-title":"Lung Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3781\/j.issn.1000-7431.2013.12.003","article-title":"The effect of Kanglaite injection in combination with gefitinib on angiogenesis in mice with Lewis lung cancer","volume":"33","author":"Shen","year":"2013","journal-title":"Tumor"},{"key":"B63","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: a double role in lung cancer cell survival?","volume":"4","author":"Suda","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/tox.22899","article-title":"Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non\u2010small cell lung cancer cells","volume":"35","author":"Tan","year":"2020","journal-title":"Environ. Toxicol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","article-title":"Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: implications for cancer therapy","volume":"85","author":"Thuya","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"B68","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12943-022-01662-1","article-title":"Costunolide is a dual inhibitor of MEK1 and AKT1\/2 that overcomes osimertinib resistance in lung cancer","volume":"21","author":"Tian","year":"2022","journal-title":"Mol. Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijbiomac.2016.10.018","article-title":"Immunomodulatory effect of APS and PSP is mediated by Ca2 + -cAMP and TLR4\/NF-\u03baB signaling pathway in macrophage","volume":"94","author":"Wang","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"105728","DOI":"10.1016\/j.phrs.2021.105728","article-title":"Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy","volume":"170","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1007\/s00432-022-04297-3","article-title":"Efficacy and safety of EGFR-TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations","volume":"149","author":"Wang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/ddr.22061","article-title":"Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K\/AKT pathway","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/13880209.2023.2292266","article-title":"Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22\/STAT3\/AKT pathway","volume":"62","author":"Wang","year":"","journal-title":"Pharm. Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/OTT.S444214","article-title":"Traditional Chinese medicine in regulating tumor microenvironment","volume":"17","author":"Wang","year":"","journal-title":"Onco Targets Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2026.5860","article-title":"IL-6: a key player in the EGFR-TKI-resistant tumor microenvironment and its therapeutic implications (Review)","volume":"68","author":"Wei","year":"2026","journal-title":"Int. J. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI\u2013targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.mcpro.2023.100624","article-title":"EGFR-T790M mutation\u2013derived interactome rerouted EGFR translocation contributing to gefitinib resistance in non-small cell lung cancer","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"key":"B80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3892\/or.2023.8509","article-title":"Andrographolide suppresses aerobic glycolysis and induces apoptotic cell death by inhibiting pyruvate dehydrogenase kinase 1 expression","volume":"49","author":"Yang","year":"2023","journal-title":"Oncol. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/1878-0261.12645","article-title":"Overcoming acquired resistance of EGFR\u2010mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol","volume":"14","author":"Zang","year":"2020","journal-title":"Mol. Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpba.2018.07.006","article-title":"Discovery of quality control markers from traditional Chinese medicines by fingerprint-efficacy modeling: current status and future perspectives","volume":"159","author":"Zhang","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B86","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1111\/jcmm.16556","article-title":"HIF\u20101\u03b1 is necessary for activation and tumour\u2010promotion effect of cancer\u2010associated fibroblasts in lung cancer","volume":"25","author":"Zhang","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.gendis.2022.10.006","article-title":"The function and mechanism of lactate and lactylation in tumor metabolism and microenvironment","volume":"10","author":"Zhang","year":"2023","journal-title":"Genes Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"116306","DOI":"10.1016\/j.jep.2023.116306","article-title":"Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula","volume":"309","author":"Zhao","year":"2023","journal-title":"J. Ethnopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1901815\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:34:04Z","timestamp":1789133644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1901815\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":88,"alternative-id":["10.3389\/fphar.2026.1901815"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1901815","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1901815"}}